BioVersys Shareholders Approve All Board Proposals, Including New Board Member and Compensation Packages
BioVersys AG announced that shareholders approved all board proposals at its annual general meeting, including the re-election of directors and election of a new board member, as the company advances its lead antibiotic candidate into Phase 3 trials.
BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company focused on developing novel antibacterial products for multi-drug resistant (MDR) infections, announced today that all proposals by its Board of Directors were approved by shareholders at the company's Annual General Meeting (AGM). The approvals include the 2025 annual report, financial statements, re-election of board members, election of a new director, and compensation packages for the board and executive committee.
Shareholders re-elected Dr. Seng Chin Mah as Chairman of the Board, along with David Hunstad, Marc Gitzinger, Marina von Schonau, and Ulrik Schulze as members. Ms. Simona Skerjanec was elected as a new member of the Board of Directors, replacing Dr. William Jenkins, who stepped down. The meeting also approved the maximum aggregate compensation for the Board of Directors until the AGM 2027 and for the Executive Committee for the financial year 2027.
Dr. Seng Chin Mah, Chairman of the Board, expressed gratitude to shareholders for their continued trust and support. He highlighted the company's progress, including achieving first-patient-first-visit (FPFV) for the global Phase 3 trial of BV100, its lead candidate targeting Acinetobacter baumannii infections. 'We are completely focused on eventually bringing this therapeutic option to patients in dire need,' he said. Mah also acknowledged Dr. Jenkins' contributions and welcomed Ms. Skerjanec to the board.
The approval of all items signals shareholder confidence in BioVersys' strategy as it advances its pipeline. The company's most advanced programs include BV100 (Phase 3) for nosocomial infections and alpibectir (Phase 2) for tuberculosis, developed in collaboration with GlaxoSmithKline (GSK) and the University of Lille. BioVersys' platforms, TRIC and Ansamycin Chemistry, aim to overcome resistance mechanisms and address high unmet medical needs in antimicrobial and microbiome fields.
The minutes and relevant documents from the AGM, including the Annual Report, are available on the company's website. The Annual Report can be accessed at https://ir.bioversys.com/investor-relations/financials/financial-reports, and AGM details are at https://ir.bioversys.com/investor-relations/governance-csr/annual-general-meeting.
This shareholder endorsement comes at a critical time as antibiotic resistance continues to rise globally, with the World Health Organization listing MDR bacteria as a top threat. BioVersys' focus on life-threatening infections positions it as a key player in the fight against superbugs, making the successful progression of its pipeline a matter of significant public health importance.